Risk of Anaphylaxis
- Anaphylaxis has been reported after administration of Palynziq and may occur at any time during treatment.
- Administer the initial dose of Palynziq under the supervision of a healthcare provider equipped to manage anaphylaxis, and closely observe patients for at least 60 minutes following injection. Prior to self-injection, confirm patient competency with self-administration, and patient’s and observer’s (if applicable) ability to recognize signs and symptoms of anaphylaxis and to administer auto-injectable epinephrine, if needed.
- Prescribe auto-injectable epinephrine. Prior to first dose, instruct the patient and observer (if applicable) on its appropriate use. Instruct the patient to seek immediate medical care upon its use. Instruct patients to carry auto-injectable epinephrine with them at all times during Palynziq treatment.
- Palynziq is available only through a restricted program called the Palynziq REMS.
Approved Risk Evaluation and Mitigation Strategies (REMS)
Patient Counseling Information
Updated June 2018